Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B13 | Q7Z5P4 | 7/20 | 0.43 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.43 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.43 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.42 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.42 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.39 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | PDE2A | O00408 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4505012 | 0.80 | HDAC1 (0.44) | NR1H2NR1H3NPBWR1P2RX7P2RY14 | |
| SCHEMBL4496912 | 0.74 | HSD17B13 (0.44) | HSD17B13P2RX7HDAC1HDAC6PDE2A | |
| SCHEMBL4516945 | 0.73 | HSD17B13 (0.42) | HSD17B13P2RX7HDAC1HDAC6 | |
| SCHEMBL1114336 | 0.70 | KDM4E (0.39) | HSD17B13NR1H2NR1H3P2RX7KDM4E | |
| SCHEMBL1114833 | 0.68 | HSD17B13 (0.38) | HSD17B13NR1H2NR1H3NPBWR1P2RX7 | |
| SCHEMBL4355638 | 0.68 | UTS2R (0.51) | HSD17B13P2RX7KDM4EALDH1A1ATM | |
| SCHEMBL18980016 | 0.65 | RAB9A (0.70) | NR1H2NR1H3NPBWR1P2RX7ALDH1A1 | |
| SCHEMBL1491106 | 0.65 | KDM4E (0.46) | NR1H2NR1H3NPBWR1P2RX7KDM4E | |
| SCHEMBL11038617 | 0.64 | NPBWR1 (0.49) | NR1H2NR1H3NPBWR1KDM4EALDH1A1 | |
| SCHEMBL5810445 | 0.64 | P2RX7 (0.51) | NR1H2NR1H3NPBWR1P2RX7KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009131956-A1 | COMPOUNDS, COMPOSITIONS AND METHODS COMPRISING TRIAZOLE DERIVATIVES | INSTITUTE FOR ONEWORLD HEALTH (US) | 2009-10-29 | — | — | WO | claimed |
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | INSTITUTE FOR ONEWORLD HEALTH | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318429-A1 | Compounds, Compositions and Methods Comprising Heteroaromatic Derivatives | CFTR, PKD1, PKD2 | HSD17B13 924/4885AVPR2 281/4885AVPR1A 837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.